Cargando…

A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents

Thyroid metastasis is a rare occurrence with cutaneous melanoma and even more uncommon with uveal melanoma. The management of such metastasis is uncertain due to its infrequency and, in the era of immunotherapy, the effect of these novel drugs on uncommon metastasis, such as to the thyroid, is unkno...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Dearbhaile Catherine, Yela, Ruben, Horgan, Noel, Power, Derek Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823504/
https://www.ncbi.nlm.nih.gov/pubmed/27110415
http://dx.doi.org/10.1155/2016/6564094
_version_ 1782425931967627264
author Collins, Dearbhaile Catherine
Yela, Ruben
Horgan, Noel
Power, Derek Gerard
author_facet Collins, Dearbhaile Catherine
Yela, Ruben
Horgan, Noel
Power, Derek Gerard
author_sort Collins, Dearbhaile Catherine
collection PubMed
description Thyroid metastasis is a rare occurrence with cutaneous melanoma and even more uncommon with uveal melanoma. The management of such metastasis is uncertain due to its infrequency and, in the era of immunotherapy, the effect of these novel drugs on uncommon metastasis, such as to the thyroid, is unknown. We report the rare case of a thyroid metastasis in a patient diagnosed with ocular melanoma initially managed with enucleation. Metastatic disease developed in the lung and thyroid gland. The case patient received the immunotherapy ipilimumab with stable disease in the thyroid and progressive disease elsewhere. The patient was then further treated with a second immunotherapy agent, pembrolizumab, and remains with stable disease one year later. We discuss the current literature on thyroid metastases from all causes and the optimal known management strategies. Furthermore, we provide an original report on the response of this disease to the novel immunomodulators, ipilimumab, and pembrolizumab with stable disease four years after initial diagnosis of ocular melanoma.
format Online
Article
Text
id pubmed-4823504
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48235042016-04-24 A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents Collins, Dearbhaile Catherine Yela, Ruben Horgan, Noel Power, Derek Gerard Case Rep Oncol Med Case Report Thyroid metastasis is a rare occurrence with cutaneous melanoma and even more uncommon with uveal melanoma. The management of such metastasis is uncertain due to its infrequency and, in the era of immunotherapy, the effect of these novel drugs on uncommon metastasis, such as to the thyroid, is unknown. We report the rare case of a thyroid metastasis in a patient diagnosed with ocular melanoma initially managed with enucleation. Metastatic disease developed in the lung and thyroid gland. The case patient received the immunotherapy ipilimumab with stable disease in the thyroid and progressive disease elsewhere. The patient was then further treated with a second immunotherapy agent, pembrolizumab, and remains with stable disease one year later. We discuss the current literature on thyroid metastases from all causes and the optimal known management strategies. Furthermore, we provide an original report on the response of this disease to the novel immunomodulators, ipilimumab, and pembrolizumab with stable disease four years after initial diagnosis of ocular melanoma. Hindawi Publishing Corporation 2016 2016-03-24 /pmc/articles/PMC4823504/ /pubmed/27110415 http://dx.doi.org/10.1155/2016/6564094 Text en Copyright © 2016 Dearbhaile Catherine Collins et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Collins, Dearbhaile Catherine
Yela, Ruben
Horgan, Noel
Power, Derek Gerard
A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents
title A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents
title_full A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents
title_fullStr A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents
title_full_unstemmed A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents
title_short A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents
title_sort rare thyroid metastasis from uveal melanoma and response to immunotherapy agents
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823504/
https://www.ncbi.nlm.nih.gov/pubmed/27110415
http://dx.doi.org/10.1155/2016/6564094
work_keys_str_mv AT collinsdearbhailecatherine ararethyroidmetastasisfromuvealmelanomaandresponsetoimmunotherapyagents
AT yelaruben ararethyroidmetastasisfromuvealmelanomaandresponsetoimmunotherapyagents
AT horgannoel ararethyroidmetastasisfromuvealmelanomaandresponsetoimmunotherapyagents
AT powerderekgerard ararethyroidmetastasisfromuvealmelanomaandresponsetoimmunotherapyagents
AT collinsdearbhailecatherine rarethyroidmetastasisfromuvealmelanomaandresponsetoimmunotherapyagents
AT yelaruben rarethyroidmetastasisfromuvealmelanomaandresponsetoimmunotherapyagents
AT horgannoel rarethyroidmetastasisfromuvealmelanomaandresponsetoimmunotherapyagents
AT powerderekgerard rarethyroidmetastasisfromuvealmelanomaandresponsetoimmunotherapyagents